Despite the contraindications, stopping treatment for HIV infection continues to be a common practice. Understanding whether T-cell proliferative capacity and phenotypic markers before treatment interruption (TI) can predict CD4+ T-cell count change and nadir during TI would be clinically useful.
Methods
This retrospective study included 27 HIV- infected patients in the chronic phase of infection while on combination antiretroviral therapy (cART) who underwent a TI. Peripheral blood mononuclear cells from a baseline pre-TI time point were screened for T-cell proliferation to cytomegalovirus (CMV) lysate, an HIV Gag p55 peptide pool as well as positive and negative control stimuli. CD28 and CD57 expression on CD4+ and CD8+ T-cells were measured.
Results
Baseline viral load, CD4+ T-cell count, pre-cART nadir CD4+ T-cell and percentage CD4+CD28+ T-cells were all predictive of the lowest CD4+ T-cell count during TI (Spearman's correlation P<0.05 for all analyses). In addition, CD4+ and CD8+ T-cells proliferation to CMV lysate, baseline CD4+ T-cell count and percentage CD4+CD57+ T-cells correlated negatively with CD4+ T-cell decrease during TI (Spearman's correlation P<0.05 for all analyses).
Conclusions
In treated chronic HIV-infected patients, pre-TI immune parameters are potential predictors for both the nadir CD4+ T-cell count and CD4+ T-cell count decrease during TI.
References
1.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.N Engl J Med1998; 338: 853–860.
2.
PhillipsA.N., StaszewskiS., LampeF.Human immunodeficiency virus rebound after suppression to <400 copies/ml during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.J Infect Dis2002; 186: 1086–1091.
3.
MocroftA., PhillipsA.N., Friis-MollerN.Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.Antivir Ther2002; 7: 21–30.
4.
PaiN.P., TulskyJ.P., LawrenceJ., ColfordJ.M.Jr., ReingoldA.L.Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.Cochrane Database Syst Rev2005; 4: CD005482.
5.
WalmsleyS., LoutfyM.Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?J Int Assoc Physicians AIDS Care (Chic Ill)2002; 1: 95–103.
6.
TuldraA., FumazC.R., FerrerM.J.Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.AIDS2001; 15: 1904–1906.
7.
LoriF., LewisM.G., XuJ.Control of SIV rebound through structured treatment interruptions during early infection.Science2000; 290: 1591–1593.
8.
RosenbergE.S., AltfeldM., PoonS.H.Immune control of HIV-1 after early treatment of acute infection.Nature2000; 407: 523–526.
9.
KaufmannD.E., LichterfeldM., AltfeldM.Limited durability of viral control following treated acute HIV infection.PLoS Med2004; 1: e36.
10.
KatlamaC., DominguezS., GourlainK.Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).AIDS2004; 18: 217–226.
11.
LawrenceJ., MayersD.L., HullsiekK.H.Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.N Engl J Med2003; 349: 837–846.
12.
LawrenceJ., HullsiekK.H., ThackerayL.M.Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.J Acquir Immune Defic Syndr2006; 43: 169–178.
13.
AnanworanichJ., Gayet-AgeronA., Le BrazM.CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.Lancet2006; 368: 459–465.
14.
MarchouB., TangreP., CharreauI.Intermittent antiretroviral therapy in patients with controlled HIV infection.AIDS2007; 21: 457–466.
15.
BoschiA., TinelliC., OrtolaniP., MoscatelliG., MorigiG., ArlottiM.CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.AIDS2004; 18: 2381–2389.
16.
DanelC., MohR., MingaA.CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.Lancet2006; 367: 1981–1989.
17.
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.CD4+ count-guided interruption of antiretroviral treatment.N Engl J Med2006; 355: 2283–2296.
18.
RuizL., ParedesR., GomezG.Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.AIDS2007; 21: 169–178.
19.
Dart Trial Team.Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.AIDS2008; 22: 237–247.
20.
TouloumiG., PantazisN., AntoniouA., StirnadelH.A., WalkerS.A., PorterK.Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.J Acquir Immune Defic Syndr2006; 42: 554–561.
21.
Holkmann OlsenC., MocroftA., KirkO.Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.HIV Med2007; 8: 96–104.
22.
DeeksS.G., WrinT., LieglerT.Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.N Engl J Med2001; 344: 472–480.
23.
MiguelesS.A., LaboricoA.C., ShupertW.L.HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.Nat Immunol2002; 3: 1061–1068.
24.
YounesS.A., Yassine-DiabB., DumontA.R.HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.J Exp Med2003; 198: 1909–1922.
25.
GambergJ., PardoeI., BowmerM.I., HowleyC., GrantM.Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression.Immunol Cell Biol2004; 82: 38–46.
26.
Choremi-PapadopoulouH., ViglisV., GargalianosP., KordossisT., Iniotaki-TheodorakiA., KosmidisJ.Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection.J Acquir Immune Defic Syndr1994; 7: 245–253.
27.
HatzakisG., TsoukasC.Neural networks in the assessment of HIV immunopathology.Proc AMIA Symp2001: 249–253.
28.
BrenchleyJ.M., KarandikarN.J., BettsM.R.Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.Blood2003; 101: 2711–2720.
29.
PalmerB.E., BlyveisN., FontenotA.P., WilsonC.C.Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction.J Immunol2005; 175: 8415–8423.
30.
SkiestD.J., SuZ., HavlirD.V.Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.J Infect Dis2007; 195: 1426–1436.
31.
OstrowskiS.R., GerstoftJ., PedersenB.K., UllumH.A low level of CD4+CD28+ T cells is an independent predictor of high mortality in human immunodeficiency virus type 1-infected patients.J Infect Dis2003; 187: 1726–1734.
32.
RuddC.E.Upstream-downstream: CD28 cosignaling pathways and T cell function.Immunity1996; 4: 527–534.
33.
BorthwickN.J., BofillM., GombertW.M.Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells.AIDS1994; 8: 431–441.
34.
GiorgiJ.V., HultinL.E., McKeatingJ.A.Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.J Infect Dis1999; 179: 859–870.
35.
HuntP.W., BrenchleyJ., SinclairE.Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.J Infect Dis2008; 197: 126–133.
36.
DoisneJ.M., UrrutiaA., Lacabaratz-PorretC.CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.J Immunol2004; 173: 2410–2418.
37.
SchrierR.D., WileyC.A., SpinaC., McCutchanJ.A., GrantI.Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center.J Clin Invest1996; 98: 731–740.
38.
PapagnoL., SpinaC.A., MarchantA.Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.PLoS Biol2004; 2: e20.
39.
WilsonJ.D., ImamiN., WatkinsA.Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease.J Infect Dis2000; 182: 792–798.
40.
KiepielaP., NgumbelaK., ThobakgaleC.CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.Nat Med2007; 13: 46–53.
41.
ClericiM., StocksN.I., ZajacR.A.Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.J Clin Invest1989; 84: 1892–1899.
42.
RinaldoC.R.Jr., LiebmannJ.M., HuangX.L.Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.J Infect Dis1999; 179: 329–336.
43.
Al-HarthiL., SiegelJ., SpritzlerJ., PottageJ., AgnoliM., LandayA.Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.AIDS2000; 14: 761–770.
44.
AppayV., Rowland-JonesS.L.Premature ageing of the immune system: the cause of AIDS?Trends Immunol2002; 23: 580–585.
